Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
Key result
Tirzepatide cuts CV death or worsening heart failure ~38% vs. placebo in obese HFpEF.
- HR 0.62
- 95% CI 0.41-0.95
- P=0.026
- n=731
Figures
Why the study?
Patients with HFpEF and obesity experience significant disability and frequent exacerbations, prompting evaluation of tirzepatide across a comprehensive suite of clinical endpoints.
Does tirzepatide reduce cardiovascular death or worsening heart failure and improve health status in patients with heart failure with preserved ejection fraction and obesity?
Key Points
- To determine whether tirzepatide improves cardiovascular outcomes, health status, functional capacity, and quality of life in patients with heart failure, preserved ejection fraction, and obesity.
- In a double-blind trial (NCT04847557), 731 patients with class II to IV heart failure, ejection fraction ≥50%, and BMI ≥30 kg/m² across 129 centers in 9 countries were randomized to subcutaneous tirzepatide (up to 15 mg weekly; n=364) or placebo (n=367) for a median of 104 weeks.
- Primary endpoints were the combined risk of cardiovascular death or worsening heart failure events and change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) at 52 weeks.
- Tirzepatide reduced the risk of cardiovascular death or worsening heart failure compared with placebo (HR, 0.62 [95% CI, 0.41–0.95]; P=0.026), with sensitivity hazard ratios ranging from 0.41 to 0.67.
- At 52 weeks, tirzepatide increased KCCQ-CSS by 6.9 points (95% CI, 3.3–10.6; P<0.001) and 6-minute walk distance by 18.3 m (95% CI, 9.9–26.7; P<0.001).
- Tirzepatide improved EQ-5D-5L index by 0.06 (95% CI, 0.03–0.09; P<0.001), favored New York Heart Association class (proportional OR, 2.26 [95% CI, 1.54–3.31]; P<0.001), and reduced heart failure medication burden (P=0.015).
Study Design
Type
RCT (n=731)
Blinding
Double-blind
Randomization
1:1
Multicenter
Yes
Structured PICO
Does tirzepatide reduce cardiovascular death or worsening heart failure and improve health status in patients with heart failure with preserved ejection fraction and obesity?
P
Population
731 adults with heart failure with preserved ejection fraction (LVEF ≥50%) and obesity (BMI ≥30 kg/m2), mean age 65.2 years, followed for a median of 104 weeks.
I
Intervention
Tirzepatide titrated up to 15 mg subcutaneous weekly added to usual therapy
C
Comparator
Matching placebo subcutaneous weekly added to usual therapy
O
Outcome
Time to first worsening HF event or cardiovascular death, and change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) at 52 weekscomposite
Main Result
Hazard Ratio: 0.62 (95% CI 0.41–0.95)
p-value: p=0.026
In patients with heart failure with preserved ejection fraction and obesity, tirzepatide significantly reduced the risk of cardiovascular death or worsening heart failure and comprehensively improved health status, functional capacity, and quality of life.
Limitations
- The effects on KCCQ-CSS, 6MWD, EQ-5D-5L health state index, PGIS Overall Health, and NYHA functional class were designed to be assessed only at 24 and 52 weeks, warranting further study of durability beyond 1 year.
Ask about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This is the first trial to demonstrate that a medication can change the clinical trajectory of the disease in patients with HFpEF and obesity.”
“Essentially, obesity-related HFpEF is a disease of angry adipocytes. These are very angry cells. They are in full-scale endocrine rebellion and the rest of the body suffers. There are data that GIP receptor agonism has an additional anti-inflammatory effect in addition to GLP-1, but these are lab data and we do not yet know how that translates into the clinical setting.”
“In my mind, this really is a practice-changing trial and cements incretin-based therapies as one of the cornerstones of obesity-HFpEF treatment. This is a study that isn't just targeted at a small subgroup of patients with HFpEF. This is a study that is going to affect how we think about the majority of patients with HFpEF.”
Implication
Supports tirzepatide initiation in obesity-HFpEF; provides first RCT evidence of outcome benefit with dual GIP/GLP-1 agonism.
Abstract
BACKGROUND: Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical end points, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden, in these patients. METHODS: We randomized (double-blind) 731 patients with class II to IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m 2 to tirzepatide (titrated up to 15 mg SC weekly; n=364) or placebo (n=367) added to background therapy for a median of 104 weeks (quartile 1, 66; quartile 3, 126 weeks). The primary end points were whether tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. The current expanded analysis included sensitivity analyses of the primary end points, 6-minute walk distance, EQ-5D-5L health state index, Patient Global Impression of Severity Overall Health score, New York Heart Association class, use of heart failure medications, and a hierarchical composite based on all-cause death, worsening heart failure, and 52-week changes in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and 6-minute walk distance. RESULTS: Patients were 65.2±10.7 years of age; 53.8% (n=393) were female; body mass index was 38.2±6.7 kg/m 2 ; Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 53.5±18.5; 6-minute walk distance was 302.8±81.7 m; and 53% (n=388) had a worsening heart failure event in the previous 12 months. Compared with placebo, tirzepatide produced a consistent beneficial effect across all composites of death and worsening heart failure events, analyzed as time to first event (hazard ratios, 0.41–0.67). At 52 weeks, tirzepatide increased the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score by 6.9 points (95% CI, 3.3–10.6; P <0.001), 6-minute walk distance 18.3 meters (95% CI, 9.9–26.7; P <0.001), and EQ-5D-5L 0.06 (95% CI, 0.03–0.09; P <0.001). The tirzepatide group shifted to a more favorable Patient Global Impression of Severity Overall Health score (proportional odds ratio, 1.99 [95% CI, 1.44–2.76]) and New York Heart Association class (proportional odds ratio, 2.26 [95% CI, 1.54–3.31]; both P <0.001) and required fewer heart failure medications ( P =0.015). The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio, 1.63 [95% CI, 1.17–2.28]; P =0.004). CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance, and well-being; and reduced symptoms and medication burden in patients with heart failure with preserved ejection fraction and obesity. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04847557.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Zile et al. (2024) conducted an RCT in Heart failure with preserved ejection fraction and obesity (n=731). Tirzepatide vs. Placebo was evaluated on Composite of cardiovascular death or worsening heart failure (HR 0.62, 95% CI 0.41-0.95, p=0.026). Tirzepatide reduced the risk of cardiovascular death or worsening heart failure by 38% and significantly improved health status, functional capacity, and quality of life compared to placebo in patients with heart failure with preserved ejection fraction and obesity.